Rachel Brough

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

Journal: Molecular cancer therapeutics

Published: February 18, 2026

LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.

LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.

Journal: Cancer research

Published: August 06, 2025

LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.

LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.

Journal: Cancer research

Published: August 06, 2025

Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells.

Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells.

Journal: iScience

Published: June 13, 2025

Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets.

Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets.

Journal: Science advances

Published: March 26, 2025

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Journal: Nature communications

Published: December 04, 2024

PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.

PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.

Journal: Oncogene

Published: June 17, 2024

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.

Journal: Cell reports. Medicine

Published: May 02, 2024

The transcriptomic architecture of common cancers reflects synthetic lethal interactions.

The transcriptomic architecture of common cancers reflects synthetic lethal interactions.

Journal: Nature genetics

Published: April 18, 2024

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.

Journal: bioRxiv : the preprint server for biology

Published: April 02, 2024

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 20, 2024

Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors.

Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors.

Journal: Cancer research

Published: November 16, 2023

Showing 1-12 of 58

Last Updated: 09/26/2026